As will be discussed later in this review, CD30-targeted therapy has dramatically impacted the treatment of PTCL through the CD30-directed ADC brentuximab vedotin. Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.